ArticleAntimicrobial agents and chemotherapy2024
Synergy of lytic phage pB23 and meropenem combination against carbapenem-resistant
Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Antibiotic-induced cellular enlargement drives phage synergy and resensitizes carbapenem-resistantMicrobiology spectrum · 2026Article
- Modeling Phage-Antibiotic Synergy, Innate Immunity, and Phage Resistance in Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Phage Therapy in Combating Multidrug-Resistant Gram-Negative Pathogens: A Scoping Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Phage Therapy: Targeting the Gut Microbiota for the Treatment of Acute Pancreatitis.Journal of gastroenterology and hepatology · 2026Review
- Antibiotic resistant Achromobacter xylosoxidans are highly susceptible to bacteriophages and often are killed synergistically by phage/antibiotic combinations.Research square · 2026Article
- Isolation and characterization of a novel phage AbT1 and evaluating its anti-biofilm activity and antibiotic synergy.Molecular biology reports · 2026Article
- Isolation and Characterization of the New Lytic Bacteriophage KEC4 AgainstMicroorganisms · 2026Article
- Article
- Phage-quinolone synergy: mechanisms, clinical strategies, and translational prospects.Frontiers in microbiology · 2026Review
- Detachable dissolving microneedles loaded withFrontiers in microbiology · 2026Article
- Bacteriophages targetingFrontiers in microbiology · 2026Review
- Advances in phage therapy forFrontiers in microbiology · 2026Review
- Isolation and characterization of two novel phages with lytic activity against multidrug-resistant Acinetobacter baumannii strains: potential for phage therapy.Scientific reports · 2025Article
- Isolation and identification of a newly discovered broad-spectrum Acinetobacter baumannii phage and therapeutic validation against pan-resistant Acinetobacter baumannii.Virologica Sinica · 2025Article
- Adjunctive phage therapy improves antibiotic treatment of ventilator-associated-pneumonia with Pseudomonas aeruginosa.Nature communications · 2025Article
- Bacteriophage Indie resensitizes multidrug-resistant Acinetobacter baumannii to antibiotics in vitro.Scientific reports · 2025Article
- Article
- The Evolution of Antimicrobial Resistance inAntibiotics (Basel, Switzerland) · 2025Review
- Synergistic effects of bacteriophage cocktail and antibiotics combinations against extensively drug-resistant Acinetobacter baumannii.BMC infectious diseases · 2024Article
- Phage Therapy: An Alternative Approach to Combating Multidrug-Resistant Bacterial Infections in Cystic Fibrosis.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phage-antibiotic combination treatment is a novel noteworthy drug delivery method in anti-infection. In the current study, we have isolated a new phage, pB23, against carbapenem-resistant Acinetobacter baumannii 2023. Synergistic antibacterial effect between phage pB23 and meropenem combination could be more stable, using moderate doses of phage (multiplicity of infection ranging from 0.1 to 1,000) based on results of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.